Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSahin, Tolga
dc.contributor.authorOral, Alihan
dc.contributor.authorTurker, Fatih
dc.contributor.authorKocak, Erdem
dc.date.accessioned2020-12-02T18:01:34Z
dc.date.available2020-12-02T18:01:34Z
dc.date.issued2020
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000019492
dc.identifier.urihttp://hdl.handle.net/11446/3658
dc.descriptionWOS: 000525195500066en_US
dc.descriptionPubMed: 32176089en_US
dc.description.abstractDespite many studies, the molecular mechanisms of hepatocellular carcinoma (HCC) development remain unclear. Thyroid hormone (TH) levels may vary in many chronic diseases including cirrhosis. the aim of this study was to evaluate TH status in patients with cirrhosis and HCC and to investigate the relationship between THs and HCC development. Five hundred seventy-seven patients with cirrhosis who applied to Demiroglu Bilim University, Faculty of Medicine, Gastroenterology Department between 2004 and 2019 were included the study. Three hundred sixty-seven patients who applied to Internal Medicine Unit for general health check-up were included in the study as healthy control group. Demographic, laboratory, and imaging findings of study groups were retrospectively reviewed and recorded from hospital information system. in the cirrhosis group, 252 patients had HCC (43.67%), and 325 patients had non-HCC cirrhosis (56.33%). Free thyroxine (FT4) levels were higher in the control group than in the cirrhotic group but there was no significant difference (P = .501). Thyroid-stimulating hormone (TSH) and FT4 levels were similar between groups, while free triiodothyronine (FT3) levels were significantly different between HCC group, non-HCC cirrhosis group, and control group (P = .299 for TSH, P = .263 for FT4, P < .001 for FT3). FT3 levels were significantly higher in HCC group than non-HCC cirrhosis group, but significantly lower than control group (P < .05). Our study confirmed the presence of hypothyroidism in cirrhosis patients and clearly demonstrated a strong relationship between FT3 levels and HCC development.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.identifier.doi10.1097/MD.0000000000019492en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcirrhosisen_US
dc.subjecthepatocellular carcinomaen_US
dc.subjecthypothyroidismen_US
dc.subjectthyroid hormonesen_US
dc.titleCan hypothyroidism be a protective factor for hepatocellular carcinoma in cirrhosis?en_US
dc.typearticleen_US
dc.relation.journalMedicineen_US
dc.departmentDBÜen_US
dc.identifier.issue11en_US
dc.identifier.volume99en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Sahin, Tolga; Kocak, Erdem] Demiroglu Bilim Univ, Fac Med, Dept Gastroenterol, Buyukdere St 120, TR-34394 Istanbul, Turkey; [Oral, Alihan; Turker, Fatih] Demiroglu Bilim Univ, Fac Med, Dept Internal Med, Istanbul, Turkeyen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster